Status epilepticus

SciSparc Ltd. Announces Closing of $10 Million Private Placement Priced At-the-Market

Retrieved on: 
Wednesday, June 1, 2022
Exercise, Company, Securities Act of 1933, Central nervous system, Status epilepticus, Security (finance), Autism, U.S. Securities and Exchange Commission, Pain, Sale, GLOBE, CBD, Tourette syndrome, NASDAQ, TEL, SEC, Alzheimer's disease, Exclusive, Agitation, THC, Pharmaceutical industry, Nasdaq

In connection with the private placement, the Company issued 3,546,100 units and pre-funded units at a purchase price of $2.82 per unit (or $0.001 less per pre-funded unit), priced at-the-market under Nasdaq rules.

Key Points: 
  • In connection with the private placement, the Company issued 3,546,100 units and pre-funded units at a purchase price of $2.82 per unit (or $0.001 less per pre-funded unit), priced at-the-market under Nasdaq rules.
  • Aegis Capital Corp. acted as the Exclusive Placement Agent for thePrivate Placement.
  • SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists.
  • SciSparcs focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.

NEURELIS TO HIGHLIGHT VALTOCO (DIAZEPAM NASAL SPRAY) CIV DEVELOPMENT PROGRAM Updates AT 16TH EILAT CONFERENCE

Retrieved on: 
Tuesday, May 31, 2022
Food, Coma, Seizure, Mania, Pharmacokinetics, CNS, Conference, International League Against Epilepsy, Headache, Schizophrenia, Metabolic acidosis, Somnolence, Hemangioma, Suicidal ideation, Anticonvulsant, Hypoventilation, Depression, Boxed warning, SAN, Drug, Diazepam, Administration, Death, Science, Multimedia, Health, Patient, ROCK, Adult, Schedule, FDA, Status epilepticus, Epilepsy, Benzodiazepine, Central nervous system, AND, Therapy, Risk, CCMS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, AED, View, Intraocular pressure, Device, Benzyl alcohol, Contraindication, Safety, Technology, Glaucoma, Behavior, Pharmaceutical industry, Dietary supplement, Birth control, Medicine, Gustav Neuring

The VALTOCO development program included 175 patients and treated more than 4,000 seizures.

Key Points: 
  • The VALTOCO development program included 175 patients and treated more than 4,000 seizures.
  • Currently, the Stellina trial, a Phase 1/2a open-label study of VALTOCO, is investigating pharmacokinetics, safety, and tolerability in pediatric epilepsy patients ages 2 to 5.
  • For more information on Neurelis, please visit www.neurelis.com .For the latest scientific information on VALTOCO, please visit www.neurelismedicalaffairs.com .
  • For patients using VALTOCO more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue VALTOCO.

SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems

Retrieved on: 
Tuesday, May 31, 2022
Pain, Company, CBD, Private Securities Litigation Reform Act, Peripheral nervous system, TEL, U.S. Securities and Exchange Commission, Morphine, Agitation, NASDAQ, Tourette syndrome, Cannabinoid, Research, Brain, Status epilepticus, Intention, Gel, Alzheimer's disease, CB2, Central nervous system, Trap, Technology, Safety, Chronic pain, Nasal spray, THC, Autism, SEC, Risk, Annual report, GLOBE, Pharmaceutical industry, Medical device

TEL AVIV, Israel, May 31, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced it has signed a collaboration agreement with Polyrizon Ltd., a biotech company focused on the development of innovative medical device hydrogels delivered in the form of nasal sprays (“Polyrizon”).

Key Points: 
  • SciSparc s top-tier investigational drug candidate, SCI-160, is an innovative and proprietary, non-opioid, CB2 receptor (CB2R) agonist intended for the treatment of pain.
  • By using this state-of-the-art drug delivery technology with SciSparcs proprietary SCI-160 platform, the goal of the collaboration is to develop a proprietary intranasal formulation aimed at maintaining effective concentrations of SCI-160 in the brain to significantly relieve pain.
  • Partnering with Polyrizon and taking advantage of their innovative delivery technology may create mutual opportunities to develop treatments for pain."
  • SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists.

SciSparc Announces Pricing of $10 Million Private Placement Priced At-the-Market

Retrieved on: 
Friday, May 27, 2022
Exclusive, Pain, Company, CBD, Private Securities Litigation Reform Act, TEL, U.S. Securities and Exchange Commission, Exercise, Agitation, NASDAQ, Tourette syndrome, Research, Securities Act of 1933, Status epilepticus, Intention, Alzheimer's disease, Central nervous system, Sale, THC, Autism, SEC, Security (finance), Risk, Annual report, GLOBE, Pharmaceutical industry, Nasdaq

The offering is expected to close on or about June 1, 2022, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The offering is expected to close on or about June 1, 2022, subject to the satisfaction of customary closing conditions.
  • Aegis Capital Corp. is acting as the Exclusive Placement Agent in connection with the offering.
  • SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists.
  • For example, SciSparc is using forward-looking statements when it discusses the closing of the private placement investment.

SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome

Retrieved on: 
Thursday, May 26, 2022
Pain, Company, Ethics, Population, CBD, Private Securities Litigation Reform Act, TEL, Learning, U.S. Securities and Exchange Commission, Agitation, Yale Global Tic Severity Scale, Patient, Tel Aviv Sourasky Medical Center, NASDAQ, Tourette syndrome, Phase, Quality of life, Clinical trial, Ministry, Adult, Ethics committee, Tic, Research, Ministry of Health (Saudi Arabia), Hannover Medical School, Status epilepticus, Intention, Alzheimer's disease, Central nervous system, Technology, Safety, THC, Movement, Autism, Yale University, SEC, Risk, Annual report, GLOBE, Pharmaceutical industry, Medical device, TS, Health

TEL AVIV, Israel, May 26, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it received Ethics Committee approvals from Hannover Medical School in Hannover, Germany, and the Tel Aviv Sourasky Medical Center, in Tel Aviv, Israel, to conduct the Company’s Phase IIb clinical study for SCI-110 in patients suffering from Tourette Syndrome ("TS"). The Company is evaluating additional clinical sites to join the Phase 2b trial to expedite patient enrollment in a timely manner.

Key Points: 
  • The Company is evaluating additional clinical sites to join the Phase 2b trial to expedite patient enrollment in a timely manner.
  • We are delighted and honored to receive Ethics Committee approval, an important step toward initiation of our Phase IIb trial in TS, commented Oz Adler, SciSparc's Chief Executive Officer.
  • With onset before age 18, about half to two-thirds of TS cases improve during adolescence, while adults are generally more severe patients.
  • SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists.

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 12, 2022
Health, Pharmaceutical, Biomedical Advanced Research and Development Authority, Assistant, Office of Inspector General, U.S. Department of Health and Human Services, Food, Research, U.S. Securities and Exchange Commission, Lennox–Gastaut syndrome, Epilepsy, Ovid, CDD, Patient, Oak Tree, Orion, Human services, RSE, Oaktree Capital Management, Caregiver, FDA, Patent, Status epilepticus, Orion Corporation, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, RAISE, Medication, Marinus, Therapy, PRV, Development, Office of the Assistant Secretary for Preparedness and Response, Security (finance), TSC, IP, BARDA, Pharmaceutical industry, Medical imaging, Online gambling, Target

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2022.

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the first quarter ended March 31, 2022.
  • Its been a productive year thus far as we prepare for our first commercial launch and make important advancements across our clinical programs.
  • At March 31, 2022, the company had cash and cash equivalents of $126.3 million, compared to $122.9 million at December 31, 2021.
  • Marinus recognized $14.2 million in revenue for the three months ended March 31, 2022, as compared to $1.8 million for the three months ended March 31, 2021.

Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome

Retrieved on: 
Thursday, May 12, 2022
Fenfluramine, Fever, Pain, Company, Population, Bright Minds In Action Learning Village, Seizure, Status epilepticus, Indian stock exchange, DS, News, Epilepsy, Dravet syndrome, Disorder, RSU, Psilocybin, RSU 1, Depression, Legislation, FDA, Ingestive behaviors, Brain, Cannabidiol, PTSD, SCN1A, Nicotine, Board, Central nervous system, Drug development, 2-Methyl-5-hydroxytryptamine, Impulsivity, Coronavirus Scientific Advisory Board (Turkey), Director, Lists of diseases, Achievement, Pharmaceutical industry, Risk management, Serotonin

VANCOUVER, British Columbia, May 12, 2022 (GLOBE NEWSWIRE) --  Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that the Company will host a symposium with Key Opinion Leaders on Dravet Syndrome and recent therapeutic developments within the competitive landscape.

Key Points: 
  • All securities issued are further subject to a hold period of four months and one day from the date of issuance.
  • BMB-101, a 5-HT2C selective and biased agonist, has demonstrated compelling activity in a host of in-vitro and in-vivo non-clinical tests.
  • Dravet syndrome is an epilepsy syndrome that begins in infancy or early childhood and can include a spectrum of symptoms ranging from mild to severe.
  • Dravet syndrome affects an estimated 1:15,700 individuals in the U.S., or 0.0064% of the population (Wu 2015).

Marinus Pharmaceuticals Announces Resumption of Phase 3 RAISE Trial in Status Epilepticus

Retrieved on: 
Thursday, May 5, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, BARDA, COVID-19, Data monitoring committee, RSE, U.S. Securities and Exchange Commission, Randomness, Forward-looking statement, Private Securities Litigation Reform Act, Brain, Epilepsy, EMA, RAISE, Development, Human services, Company, Biomedical Advanced Research and Development Authority, Food, Safety, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, SE, Patient, Security (finance), Office of Inspector General, U.S. Department of Health and Human Services, Status epilepticus, Clinical trial, FDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Benzodiazepine, Adult, Marinus, Prodrug, GABAA, Medication, IV, Assistant, Office of the Assistant Secretary for Preparedness and Response, Ganaxolone, Pharmaceutical industry

Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has resumed screening and recruitment for the Phase 3 RAISE (Randomized Therapy in Status Epilepticus) trial in refractory status epilepticus (RSE).

Key Points: 
  • Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has resumed screening and recruitment for the Phase 3 RAISE (Randomized Therapy in Status Epilepticus) trial in refractory status epilepticus (RSE).
  • The company continues to expect topline RAISE trial results in the second half of 2023.
  • Marinus announced in February that it was pausing recruitment in the RAISE trial after routine stability monitoring showed visible particulates of aluminum phosphate in the drug solution.
  • The resupply will also allow the Phase 2 RESET (Researching Established Status Epilepticus Treatment) trial to continue to advance.

PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs

Retrieved on: 
Thursday, May 5, 2022
Complex regional pain syndrome, Status epilepticus, Cito Culver, University, ANDA, Lou, GLOBE, Analgesic, Company, Ketamine, Professor, Infusion, CSE, United States Patent and Trademark Office, Anesthesia, Administration, Amyotrophy, FDA, Bipolar Integrated Technology, Patent, Pain disorder, OTCQB, Betaine, Method, Efficiency, Center, Holding, Mental health, Technology, Pharmaceutical industry, Fine chemical, Amyotrophic lateral sclerosis

The Company gained exclusive worldwide development and commercial rights of the Patent along with Europe patent no.

Key Points: 
  • The Company gained exclusive worldwide development and commercial rights of the Patent along with Europe patent no.
  • Fabio Chianelli, Chief Executive Officer of PharmaTher, commented: Our goal is to become the leader in specialty ketamine pharmaceuticals.
  • The recent grant of the U.S. patent strengthens our patent portfolio of novel uses, delivery forms, formulations, and production processes of ketamine and ketamine analogs to serve the unmet medical needs for mental health, neurological and pain disorders, and surgery.
  • In addition to improving the production process of racemic ketamine, the Patent provides various methods for synthesizing ketamine analogs (i.e.

SciSparc Files Annual Report for Year Ended December 31, 2021 and Provides Corporate Update

Retrieved on: 
Monday, May 2, 2022
Mission statement, THC, Private Securities Litigation Reform Act, Autism, Pain, U.S. Securities and Exchange Commission, Nasdaq, NASDAQ, GLOBE, Company, Tourette syndrome, Annual report, Alzheimer's disease, TEL, Agitation, Risk, Form 20-F, Status epilepticus, Intention, SEC, CBD, Central nervous system, Pharmaceutical industry

Entered into a collaboration agreement with ClearMind Medicine Inc. for the development of innovative psychedelic-based pharmaceuticals

Key Points: 
  • Entered into a collaboration agreement with ClearMind Medicine Inc. for the development of innovative psychedelic-based pharmaceuticals
    Oz Adler, SciSparc's Chief Executive Officer, commented, "2021 was a turnaround year for SciSparc.
  • We successfully up-listed to the Nasdaq stock exchange and raised approximately $8 million from high quality investors.
  • Operationally, we expanded our IP protection in key territories and advanced our programs in Tourette syndrome, Alzheimer's disease and Agitation, Status Epilepticus and pain.
  • SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists.